Table 2.
Characteristics of the Study Populations by Diagnosis
| Diagnosis |
|||||||
|---|---|---|---|---|---|---|---|
| Characteristic | Hypertension (n=457,395) | Hypercholesterolemia (n=207,676) | Type 2 Diabetes (n=105,225) | Osteoporosis (n=42,007) | Hypothyroidism (n=37,606) | Gout (n=9715) | Seizure Disorders (n=4984) |
| Mean ± SE | |||||||
| Age (yrs) | 59.9 ± 0.02 | 57.7 ± 0.02 | 58.5 ± 0.04 | 64.8 ± 0.6 | 54.0 ± 0.07 | 58.7 ± 0.14 | 50.1 ± 0.24 |
| Comorbidity scorea | 0.67 ± 0.00 | 0.56 ± 0.00 | 0.81 ± 0.00 | 0.69 ± 0.00 | 0.55 ± 0.00 | 0.73 ± 0.00 | 1.14 ± 0.01 |
|
| |||||||
| No. (%) of Patients | |||||||
| Sex | |||||||
| Male | 204,913 (44.8) | 107,576 (51.8) | 54,717 (52.0) | 3025 (7.2) | 7672 (20.4) | 7529 (77.5) | 2088 (41.9) |
| Female | 252,482 (55.2) | 100,100 (48.2) | 50,508 (48.0) | 38,982 (92.8) | 29,934 (79.6) | 2186 (22.5) | 2896 (58.1) |
| Type of health planb | |||||||
| Comprehensive | 161,003 (35.2) | 66,422 (32.0) | 35,987 (34.2) | 17,999 (42.9) | 11,461 (30.5) | 3274 (33.7) | 1585 (31.8) |
| Exclusive provider organization | 3659 (0.8) | 2411 (1.2) | 631 (0.6) | 272 (0.7) | 477 (1.3) | 49 (0.5) | 52 (1.0) |
| Health maintenance organization | 35,219 (7.7) | 16,395 (7.9) | 10,207 (9.7) | 1253 (3.0) | 2524 (6.7) | 787 (8.1) | 509 (10.2) |
| Point of service | 59,004 (12.9) | 26,393 (12.7) | 14,205 (13.5) | 3726 (8.9) | 5115 (13.6) | 1263 (13.0) | 661 (13.3) |
| Preferred provider organization | 172,438 (37.7) | 81,395 (39.2) | 37,986 (36.1) | 16,824 (40.1) | 15,217 (40.5) | 3847 (39.6) | 1810 (36.3) |
| Point of service with cap | 26,072 (5.7) | 14,660 (7.1) | 6209 (5.9) | 1933 (4.6) | 2812 (7.5) | 495 (5.1) | 367 (7.4) |
| Geographic area of residenceb | |||||||
| Northeast | 48,484 (10.6) | 22,137 (10.7) | 10,373 (9.9) | 5387 (12.8) | 3723 (9.9) | 963 (9.9) | 578 (11.6) |
| North Central | 140,878 (30.8) | 68,512 (33.0) | 32,836 (31.2) | 14,774 (35.2) | 11,771 (31.3) | 3049 (31.4) | 1490 (29.9) |
| South | 189,819 (41.5) | 79,692 (38.4) | 44,019 (41.8) | 14,438 (34.4) | 14,478 (38.5) | 3875 (39.9) | 1934 (38.8) |
| West | 78,214 (17.1) | 37,335 (18.0) | 17,997 (17.1) | 7408 (17.6) | 7634 (20.3) | 1828 (18.8) | 982 (19.7) |
| Previous drug therapyc | 289,531 (63.3) | 61,472 (29.6) | 50,403 (47.9) | 2940 (7.0) | 3610 (9.6) | 155 (1.6) | 2148 (43.1) |
| Drugs added to the initial therapyb | |||||||
| 0 | 133,102 (29.1) | 156,795 (75.5) | 46,720 (44.4) | 39,453 (93.9) | 34,485 (91.7) | 9433 (97.1) | 2088 (41.9) |
| 1 | 146,824 (32.1) | 40,705 (19.6) | 37,565 (35.7) | 2554 (6.1) | 2933 (7.8) | 282 (2.9) | 1714 (34.4) |
| ≥ 2 | 177,469 (38.8) | 10,176 (4.9) | 20,940 (19.9) | 0 (0.0) | 188 (0.5) | 0 (0.0) | 1182 (23.7) |
SE = standard error.
a
Comorbidity scores equal the sum of medical care risk based on diagnoses; a higher score indicates higher risk.
b
Percentages may not equal 100% due to rounding.
c
History of drug therapy for the condition in the year before the newly started treatment.